Compare NNN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNN | LNTH |
|---|---|---|
| Founded | 1984 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 4.9B |
| IPO Year | 1995 | 2014 |
| Metric | NNN | LNTH |
|---|---|---|
| Price | $42.57 | $74.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $44.17 | ★ $83.20 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.07 | ★ 3.41 |
| Revenue | ★ $926,213,000.00 | $343,374,000.00 |
| Revenue This Year | $5.70 | N/A |
| Revenue Next Year | $5.21 | $13.47 |
| P/E Ratio | ★ $20.55 | $22.42 |
| Revenue Growth | ★ 6.55 | 3.62 |
| 52 Week Low | $35.80 | $47.27 |
| 52 Week High | $46.03 | $108.86 |
| Indicator | NNN | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 31.87 | 45.49 |
| Support Level | $41.65 | $70.73 |
| Resistance Level | $43.18 | $83.70 |
| Average True Range (ATR) | 0.74 | 3.07 |
| MACD | -0.44 | -0.93 |
| Stochastic Oscillator | 5.32 | 14.79 |
NNN REIT Inc is a real estate investment trust that acquires, owns, invests in, and develops high-quality properties mainly leased under long-term net leases with minimal capital expenditure requirements. The company focuses mainly on retail properties, with a portfolio including convenience stores, automotive service properties, restaurants, theatres, entertainment venues, dealerships, and other retail-related assets. Primary business objectives emphasize retail properties, and it may invest in a wide variety of property and tenant types, leases, mortgages, loans secured by personal property, loans secured by partnership or membership interests, and securities of other REITs or other issuers.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.